Alto Neuroscience, Inc.
Alto Neuroscience, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on December 12, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.
Cash runway is approximately 27 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 8 concluded trials, 75% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| December 12, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| December 15, 2026 | Study of ALTO-300 in MDD | Trial Milestone | Phase 2 |
| September 15, 2027 | ALTO-100 in Bipolar Disorder With Depression (BD-D) | Trial Milestone | Phase 2 |
| November 15, 2027 | ALTO-207 in Adults With Treatment-resistant Depression (TRD) | Trial Milestone | Phase 2 |
Track ANRO alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open ANRO in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| August 27, 2026 | 8-K filed: Leadership change | Corporate | — |
| August 12, 2026 | Quarterly results filed (8-K) | Earnings | — |
| July 14, 2026 | 8-K filed: Material agreement | Corporate | — |
| July 13, 2026 | Quarterly results filed (8-K) | Earnings | — |
| May 28, 2026 | 8-K filed: Leadership change | Corporate | — |
| May 13, 2026 | Quarterly results filed (8-K) | Earnings | — |
| May 13, 2026 | 8-K filed: Leadership change | Corporate | — |
| April 1, 2026 | 8-K filed: Other event | Filing | — |
| March 16, 2026 | Quarterly results filed (8-K) | Earnings | — |
| March 16, 2026 | 8-K filed: Material agreement, Other event | Corporate | — |
| February 15, 2026 | Study of ALTO-101 in Patients With Schizophrenia | Trial Milestone | Phase 2 |
| November 12, 2025 | Quarterly results filed (8-K) | Earnings | — |
| October 20, 2025 | 8-K filed: Material agreement, Other event | Corporate | — |
| August 13, 2025 | Quarterly results filed (8-K) | Earnings | — |
| July 8, 2025 | 8-K filed: Leadership change | Corporate | — |
| June 26, 2025 | 8-K filed: Other event | Filing | — |
| June 3, 2025 | 8-K filed: Material agreement, Other event | Corporate | — |
| May 14, 2025 | Quarterly results filed (8-K) | Earnings | — |
| April 14, 2025 | PD, PK, and Safety of ALTO-203 in Patients With MDD | Trial Milestone | Phase 2 |
| September 5, 2024 | Phase 2b Study of ALTO-100 in MDD | Trial Milestone | Phase 2 |
| May 5, 2023 | ALTO-300 in Depression | Trial Milestone | Phase 2 |
| April 26, 2023 | ALTO-300 in Depression (ALTO-300-004) | Trial Milestone | Phase 2 |
| January 13, 2023 | Pilot Decentralized Trial | Trial Milestone | Phase 2 |
| December 1, 2022 | ALTO-100 in MDD and/or PTSD | Trial Milestone | Phase 2 |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.